Deutsche Bank Increases Anacor Pharmaceuticals Price Target to $20.00 (ANAC)
Deutsche Bank lifted their target price on shares of Anacor Pharmaceuticals (NASDAQ:ANAC) from $11.00 to $20.00 in a research note issued on Friday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price objective suggests a potential upside of 85.70% from the company’s current price.
Anacor Pharmaceuticals (NASDAQ:ANAC) traded up 29.43% during mid-day trading on Friday, hitting $13.9399. The stock had a trading volume of 2,467,226 shares. Anacor Pharmaceuticals has a one year low of $3.00 and a one year high of $12.63. The stock has a 50-day moving average of $10.67 and a 200-day moving average of $7.75. The company’s market cap is $565.4 million.
Anacor Pharmaceuticals (NASDAQ:ANAC) last released its earnings data on Thursday, August 8th. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.39) by $0.03. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the company posted ($0.47) earnings per share. The company’s quarterly revenue was up 30.8% on a year-over-year basis. Analysts expect that Anacor Pharmaceuticals will post $-1.67 EPS for the current fiscal year.
Anacor Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.